MedTrace Logo

Study of the Efficacy and Safety of Longidaze® for the Treatment of Patients With External Genital Endometriosis

NCT04962620 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 149

Last updated 2021-07-22

No results posted yet for this study

Summary

A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of external genital endometriosis .

Conditions

  • External Genital Endometriosis

Interventions

DRUG

Bovhyaluronidase azoximer

Rectally or vaginally 1 suppository of Longidaze every 2 days. The main course of treatment - 10 suppositories (for 30 days). Then (according to the doctor's decision) supportive therapy is prescribed for 1 suppository 1 time in 7 days. Course of supportive treatment - 17 suppositories for another 120 days. The patients took dienogest according to the instructions for use.

Sponsors & Collaborators

  • NPO Petrovax

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-26
Primary Completion
2021-05-14
Completion
2021-08-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04962620 on ClinicalTrials.gov